CTLA4 and rheumatoid arthritis: Treatment with a soluble CTLA-4-Ig fusion protein (abatacept), which links the extracellular domain of human CTLA-4 to a fragment of the Fc part of human IgG1 (146), was successful in reducing the symptoms of rheumatoid arthritis (RA) (147).